Known targets — ChEMBL curated mechanism
GRIA1GRIA2GRIA3GRIA4SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Irampanel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irampanel SCHEMBL6879876 | 0.99 | HTR7 (0.62) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5959899 | 0.91 | TTR (0.72) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7955292 | 0.91 | TTR (0.55) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7958390 | 0.91 | TTR (0.55) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7954897 | 0.91 | HTR7 (0.56) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7955222 | 0.90 | TTR (0.54) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5736080 | 0.90 | NPSR1 (0.54) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7956790 | 0.90 | TTR (0.54) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5736045 | 0.90 | HTR7 (0.63) | HTR7NPSR1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7961594 | 0.89 | MAPT (0.59) | HTR7TTRNPSR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | claimed |
| EP-2213285-B1 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | claimed |
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | claimed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | claimed |
| WO-2004069195-A2 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS OF THE AIRWAYS | IVAX CORPORATION (US) | 2004-08-19 | — | — | WO | claimed |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250281474-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | UNIVERSITY OF THE RYUKYUS (JP) | 2025-09-11 | — | — | US | disclosed |
| US-12303549-B2 | Methods of treating or inhibiting onset of Huntington's disease | UNIVERSITY OF ROCHESTER (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| US-20240398775-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE OR FOR USE IN TREATING OVERWEIGHT OR OBESITY | UNIVERSITY OF THE RYUKYUS (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2004087161-A1 | COMBINATIONS COMPRISING ANTI-EPILEPTIC DRUGS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004069195-A2 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS OF THE AIRWAYS | IVAX CORPORATION (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | disclosed |
| US-6277872-B1 | ANTIISCHEMIC AGENTS; BRAIN DISORDERS | BOEHRINGER INGELHEIM KG (DE) | 2001-08-21 | — | — | US | disclosed |
| EP-0934288-A1 | OXADIAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017652-A1 | OXADIAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | HTR7 225/4885TTR 1770/4885NPSR1 374/4885 |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | LTB4R2, LTB4R, LTC4S | HTR7 1865/4885TTR 3517/4885NPSR1 652/4885 |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | S1PR1, S1PR2, S1PR3 | HTR7 476/4885TTR 1329/4885NPSR1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.